The raised guidance and 14% Royalty Receipts growth confirm strong underlying portfolio momentum. Watch for upcoming PDUFA dates (daraxonrasib NDA acceptance, deucrictibant April 2027) and further transaction announcements as the company deploys capital into new royalties.
Price Chart
Executive Summary
Royalty Pharma reported Q2 2026 results with Portfolio Receipts of $773M (+6% YoY) and Portfolio Cash Flow per diluted share of $1.32, beating the $1.27 consensus by 3.9%. The company raised its full-year 2026 Portfolio Receipts guidance to $3,400-$3,500 million from $3,325-$3,450 million, driven by strong 14% Royalty Receipts growth from Tremfya, Voranigo, Imdelltra, and Evrysdi.
Key Financial Metrics
Key Facts
- Portfolio Receipts of $773M in Q2 2026, up 6% YoY from $727M
- Royalty Receipts of $768M, up 14% YoY from $672M
- Portfolio Cash Flow of $736M, up 15% YoY from $641M
- EPS (Portfolio Cash Flow per share) of $1.32 vs consensus $1.27 (beat by 3.9%)
- Raised full-year 2026 Portfolio Receipts guidance to $3,400-$3,500M from $3,325-$3,450M
- Capital Deployment of $1.1B YTD; acquired royalty on AstraZeneca's cliramitug for up to $425M
- Repurchased 0.9M shares for $45M in Q2; quarterly dividend of $0.235 per share
- Net cash provided by operating activities of $728M, up 100% YoY
Financial Impact
EPS beat of ~$0.05 vs consensus; guidance midpoint raised by ~$75M; Portfolio Receipts grew 6% YoY
Risk Factors
- Concentration in cystic fibrosis franchise ($194M, ~25% of Portfolio Receipts) from Vertex
- Declining Promacta revenue due to U.S. generic competition
- High debt of $9.2B exposes to rising interest rate environment
- Milestones and other contractual receipts volatile ($5M vs $56M YoY)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001802768-26-000014 |
| Document: 0001802768-26-000014-index.html | 0001802768-26-000014 |
| Document: 0001802768-26-000014.txt | 0001802768-26-000014 |
| 8-K Data (Synthetic) | 0001802768-26-000014 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 27d ago | Press Release | $60.59 $58.47 | ▲ +3.50% | ▲ +2.38% | $57.16 (+5.66%) |
Aug 19, 2026 6w ago | Insider Cluster | $61.73 $61.80 | ▲ +0.11% | ▲ +0.50% | $57.16 (−7.40%) |
Aug 12, 2026 7w ago | 144 | $58.56 $60.58 | ▲ +3.45% | ▲ +5.41% | $57.16 (−2.39%) |
Aug 5, 2026 8w ago | 8-K | $57.75 $59.22 | ▲ +2.55% | ▲ +2.19% | $57.16 (−1.02%) |
Jul 2, 2026 13w ago | Insider Cluster | $57.77 $57.96 | ▲ +0.33% | ▼ −0.60% | $57.16 (−1.06%) |
Jul 2, 2026 13w ago | Insider Cluster | $57.77 $57.96 | ▲ +0.33% | ▼ −0.60% | $57.16 (−1.06%) |
May 28, 2026 18w ago | Insider Cluster | $55.76 $55.87 | ▲ +0.20% | ▲ +2.72% | $57.16 (+2.51%) |
May 28, 2026 18w ago | 8-K | $55.76 $54.97 | ▼ −1.42% | ▼ −1.12% | $57.16 (+2.51%) |
May 22, 2026 19w ago | Insider Cluster | $54.50 $55.18 | ▲ +1.25% | ▼ −0.41% | $57.16 (+4.88%) |
May 15, 2026 19w ago | Insider Cluster | $52.07 $53.86 | ▲ +3.44% | ▲ +1.82% | $57.16 (+9.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access